6 days Ago By ABMN Staff
Mariner LLC increased its stake in shares of Incyte Co. ( NASDAQ:INCY – Free Report ) by 19.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The firm owned 12,213 shares of the biopharmaceutical company’s stock after acquiring an additional 1,993 shares during the quarter. Mariner LLC’s holdings in Incyte were worth $843,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also bought and sold shares of the stock.
Quintet Private Bank Europe S.A. acquired a new stake in Incyte during the fourth quarter worth $26,000.
Global X Japan Co. Ltd. grew its stake in shares of Incyte by 144.
7% during the fourth quarter. Global X Japan Co. Ltd.
now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 230 shares during the last quarter. R Squared Ltd bought a new stake in shares of Incyte during the fourth quarter valued at approximately $30,000. Blue Trust Inc.
grew its stake in shares of Incyte by 124.6% during the fourth quarter. Blue Trust Inc.
now owns 593 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 329 shares during the last quarter. Finally, Bradley & Co. Private Wealth Management LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $42,000.
Institutional investors own 96.97% of the company’s stock. Insider Buying and Selling In other Incyte news, EVP Barry P.
Flannelly sold 19,807 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.
83. Following the sale, the executive vice president now owns 33,567 shares of the company’s stock, valued at approximately $2,272,150.23.
This trade represents a 37.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website .
Also, EVP Sheila A. Denton sold 599 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.
99, for a total value of $41,924.01. Following the completion of the sale, the executive vice president now directly owns 25,848 shares in the company, valued at approximately $1,809,101.
52. This represents a 2.26 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold 34,475 shares of company stock valued at $2,424,751 over the last 90 days. 17.
60% of the stock is owned by corporate insiders. Analyst Upgrades and Downgrades Check Out Our Latest Analysis on INCY Incyte Price Performance Shares of NASDAQ INCY opened at $59.52 on Tuesday.
The firm has a market cap of $11.52 billion, a P/E ratio of 220.45, a price-to-earnings-growth ratio of 0.
41 and a beta of 0.89. The company has a current ratio of 1.
97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.
Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.
95. The business’s 50 day moving average is $63.41 and its 200-day moving average is $69.
00. Incyte ( NASDAQ:INCY – Get Free Report ) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.
09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48).
Incyte had a return on equity of 0.05% and a net margin of 0.77%.
Equities research analysts predict that Incyte Co. will post 4.86 earnings per share for the current year.
Incyte Company Profile ( Free Report ) Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Featured Stories Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Incyte Co. ( NASDAQ:INCY – Free Report ). Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.
com's FREE daily email newsletter ..
